SANGEETA MARUTI BHORADE, M.D., FCCP

The pulmonary council of the ISHLT has advanced the field of lung transplantation on an

international level. As Vice Chair of the pulmonary council, I hope to continue to further

the field in new and innovative ways. I have been involved with ISHLT for

approximately 14 years. Over this time, I have gained an appreciation for the mission of

the Pulmonary Council. I am currently the Medical Director of the Lung Transplant

Program at the University of Chicago. I have been involved with clinical and

translational research in lung transplantation including the evaluation of

immunosuppression during this time. In addition to identifying clinical projects of

interest, I believe that developing collaborations both within our society as well as with

other societies will greatly enhance our productivity. I am committed to devote my time

and expertise to assist this organization to further the field of lung transplantation through

education, research and collaborations. Thank you.

CURRICULUM VITAE

SANGEETA MARUTI BHORADE, M.D., FCCP

PERSONAL DATA

Business Address: University of Chicago Medical Center and Pulmonary Clinic

5841 South Maryland Ave MC 0999

Chicago, IL 60611

Home Address: 440 North McClurg Court #422

Chicago, Il 60611

312-645-0021

Place of Birth: Chicago, IL

EDUCATION

1984-1988 University of Chicago B.A., Biology/Behavioral Science

1988-1992 University of Chicago Pritzker School of Medicine, M.D.

POSTDOCTORAL TRAINING

1992-1993 Intern, Department of Medicine, University of Chicago

1993-1995 Resident, Department of Medicine, University of Chicago

1995-1998 Fellow, Section of Pulmonary/Critical Care, University of Chicago

ACADEMIC APPOINTMENTS

1998-1999 Instructor, Department of Medicine, Loyola University Medical Center

1999-2005 Assistant professor, Department of Medicine, Loyola University Medical

1999-2005 Associate Medical Director, Loyola Lung Transplant Program 2005-present Associate Professor of Medicine, Dept of Medicine, University of Chicago

2005-present Medical Director, Lung Transplant Program, University of Chicago

BOARD CERTIFICATION AND LICENSURE

2000 Board Certified, Critical Care Medicine

2010 Board Recertification, Critical Care medicine

1997 Board Certified, Pulmonary Medicine

2008 Board Recertification, Pulmonary medicine

1995 Board Certified, Internal Medicine

2006 Board Recertification, Internal Medicine

1994 Diplomate of the National Board of Medical Examiners

Illinois License # 036-090203

HONORS AND AWARDS

2001 Boehringer-Ingelheim Leadership Award in Pulmonary Medicine

1999 Leadership development Award-ACCP

1989 University of Chicago Summer Research Neurobiology Award

1988 Graduation with Honors in Behavioral Science

1988 Howell Murray Award (Awarded to the top 10 Seniors excelling in

extracurricular activities in the College)

Morton-Murphy Award (Extracurricular Achievement in the College)

COMMITTEE MEMBERSHIP

2010-2012 ATS Ethics and Conflict of Interest Committee 2010-2011 UNOS/OPTN Thoracic Committee 2006-2011 ACCP Transplantation Network Steering Committee 2007-2009 UNET Appeal board for lung transplantation

2007- Fellowship Selection Committee Member, Section of Pulmonary/ Critical

Care, University of Chicago Medical Center

2006-2009 Gift of Hope Medical Advisory Committee Member

2006-2008 Thoracic Transplantation Committee, American Society of

Transplantation

2005-2006 Secretary/ Treasurer; Chicago Thoracic Society

2004-2005 Member, Clinical Research Advisory Committee, LUMC

2003- 2005 Member, Institutional Review Board, Loyola University Medical Center

2003-2004 Secretary/ Treasurer; Chicago Thoracic Society

2002-2005 Residency Review Committee, Loyola University Medical Center

2001-2005 Chicago Thoracic Society Programming Committee

2000-2005 Infection control Committee, Loyola University Medical Center

1999-2005 Fellowship Training Committee- Loyola University Medical Center

1999-2005 Intern Recruitment Committee- Loyola University Medical Center

1999-2005 Internal medicine interest group mentor- Loyola University Medical

Center

MEMBERSHIPS IN PROFESSIONAL SOCIETIES

1999-present American Society of Transplant Physicians

1999- present International Society of Heart and Lung Transplantation

1997- present American College of Chest Physicians (FCCP, 2000)

1995- present American Thoracic Society

1994- present American College of Physicians

TEACHING EXPERIENCE

2006- present Lecturer- Lung Transplantation. Pulmonary Fellow Conference U of Chicago.

2005- present Discussant, Internal Medicine Morning Report, U of Chicago Medical Center

2005-present Discussant, Pulmonary/ Critical Care Morning Report, U of Chicago

2005- present Discussant, Morbidity and Mortality, University of Chicago Medical Center

2005- present Lecturer, Dept of Medicine Resident Lecture Series- Lung Transplantation

2007 University of Chicago Undergraduate Course. Lung Transplantation

2007 Loyola University Medical Center. Methods of Clinical Research.

2007-present U of Chicago Nursing Education. Selection criteria for lungtransplantation.

2004 LUMC fellows grand rounds: Management of malignant pleural effusions.

2004-2005 Preceptor for 1st year medical students- Introduction to Epidemiology

2002- 2005 Preceptor for 2nd

year medical students- Physical Examination

2001 LUMC fellows grand rounds: Idiopathic pulmonary fibrosis and other

interstitial lung diseases

2003- 2005 Case Discussion-DVT/PE- 2nd

year medical students

2001- 2005 Internal medicine resident board review-Interstitial lung disease

2000-2005 Mechanisms of Human Disease Class- 2nd

year medical students

1999-2005 Introductory lecture series for pulmonary fellows-LUMC Interstitial lung disease

1998-2005 Lecture series for students/ residents rotating on the Pulmonary service-

LUMC Pulmonary hypertension, Interstitial lung disease

2003 Pulmonary Care: Hospital to Home Sponsored by Loyola University

Medical Center Department of Nursing Education and Support Services.

Idiopathic Pulmonary Fibrosis

2001 Pulmonary Care: Hospital to Home Sponsored by Loyola University

Medical Center Department of lung transplant medicine and Nursing

Education and Support Services. Asthma., Lung cancer

2001 End stage lung disease symposium; Loyola University Medical

Center(coursedirector):

2002 End stage lung disease symposium. Loyola University Medical Center (co-course

director):

1993-1995 Teaching Assistant, Physical Diagnosis

1992-1994 Medical Resident preceptor for medical students

MENTORSHIP

Scholarship and Discovery Program for Medical Students

PJ McShane (University of Chicago)

2007-2010 MD Immunosuppressive regimens in lung transplantation

Instructor University of Chicago

Jaime Villanueva (Loyola University Medical Center)

1998-2001 MD Immunosuppressive regimens after lung transplantation

Private Practice of Pulmonary and Critical Care Medicine, Chicago Metropolitan Area

Ashby Jordan (Loyola

2000-2003 MD Immunosuppressive regimens after

Private Practice of Pulmonary and

University Medical Center)

lung transplantation

Critical Care Medicine, Chicago Metropolitan Area

Andrew Yu (Loyola University Medical Center)

2001-2004 MD Assessment of pro-inflammatory cytokines after lung transplantation

Private Practice of Pulmonary and Critical Care Medicine, Chicago Metropolitan Area

Brandon Lu (Loyola University Medical Center)

2002-2005 MD Differential gene expression profiling in lung transplant recipients

Instructor, Northwestern University Medical Center

REVIEWER

1. American Journal of Respiratory and Critical Care Medicine

2. AJP: Lung Cellular and Molecular Physiology

3. Chest

4. Journal of Heart and Lung Transplantation

5. Transplantation

6. American Journal of Transplantation

7. Respiratory Medicine

8. Clinical Transplantation

9. British Medical Journal

10. Transplant Infectious Disease

11. International journal of respiratory diseases

12. Annals of Transplantation

13. Abstract reviewer for the International Society of Heart and Lung Transplantation

14. Abstract reviewer for American College of Chest Physicians

15. Grant reviewer for American College of Chest Physicians

Ad hoc grant reviewer for FDA Office of Orphan Product Development May 2011

Editorial positions 1. ISRN pulmonology

PUBLICATIONS

Peer reviewed Clinical Investigations:

1. Floreth T, Stern E, Tu Y, Stern R, Garrity ER Jr, Bhorade SM, White SR.

Differentiated transplant derived airway epithelial cell cytokines secretion is not

regulated by cyclosporine. Respir Res 2011; 12: 44.

2. Sims MW, Beers MF, Ahya VN, Kawut SM, Sims KD, Lederer DJ, Palmer SM, Wille

K, Lama V, Shah PD, Orens JB, Bhorade S, Crespo M, Weinacker A, Demissie E,

Bellamy S, Christie JD, Ware LB; for the Lung Transplant Outcomes Group. Effect

of single versus bilateral lung transplantation on plasma surfactant protein D levels in

idiopathic pulmonary fibrosis. Chest 2011 (epub)

3. Vigneswaran WT, Helenowski M, Bhorade SM, Lamounier F, Alex C, Garrity ER Jr.

Early readmission is a predictor of overall survival following isolated lung

transplantation . Int Surg 2010; 95: 299-304.

4. Diamond JM, Kawut SM, Lederer DJ, Ahya VN, Kohl B, Sonett J, Palmer SM, Crespo

M, Wille KM, Lama V, Shah PD, Orens J, Bhorade S, Weinacker A, Demissie1 E,

Bellamy S, Christie JD, and Ware LB for the Lung Transplant Outcomes Group.

Elevated Plasma Clara Cell Secretory Protein Concentration is Associated with High

Grade Primary Graft Dysfunction. Am J Transplant 2011; 11: 561-567.

5. Ahya VN, McShane PJ, Baz MA, Valentine VG, Arcasoy SM, Love RB, Seethamraju

H, Garrity E, Alex CG, Bag R, Deoliveira NC, Vigneswaran WT, Charbeneau J,

Krishnan JA, Durazo-Arvizu R, Norwick L, Bhorade S. Increased risk of venous

thromboembolism with a sirolimus based immunosuppression regimen in lung

transplantation. J Heart Lung Transplant 2011; 30: 175-181.

6. Bhorade S, Ahya VN, Baz MA, et al. Comparison of sirolimus to azathioprine in a

tacrolimus based immunosuppressive regimen in lung transplantation. Am J Respir

Crit Care Med 2011; 183: 379-387.

7. Bhorade SM, Chen H, Molinero L, et al. Decreased percentage of CD4+FoxP3+ cells

in bronchoalveolar lavage from lung transplant recipients correlates with development

of bronchiolitis obliterans syndrome. Transplantation 2010;15: 540-546.

8. Sandbo N, Kregel S, Taurin S, Bhorade S, Dulin NO. Critical role of serum response

factor in pulmonary myofibroblast differentiation induced by TGF beta. Am J Respir

Cell Mol Biol 2009; 41: 332-338.

9. Bhorade SM, et al. Cylex immunoassay levels are lower in lung transplant recipients

with infection. The Journal of Heart and Lung Transplantation 2008; 27: 990-994.

10. Vigneswaran WT, Bhorade S, Wolfe M, Pelletiere K, Garrity ER. Clinical pathway

after lung transplantation shortens hospital length of stay without affecting outcome.

Int Surg 2007; 92: 93-98.

11. Bhorade SM, et al.Elevation of IL15 protein expression in bronchoalveolar fluid in

acute lung allograft rejection. Chest 2007: 131; 533-538.

12. Lu BS, Yu AD, Zhu X, Garrity ER, Vigneswaran WT, Bhorade SM. Sequential gene

expression profiling in lung transplant recipients with chronic rejection. Chest.

2006;130:847-854

13. Villanueva J, Boukhamseen A, Bhorade, SM. Successful Use in Lung

Transplantation of an Immunosuppressive Regimen Aimed at Reducing Target Blood

Levels of Tacrolimus and Sirolimus Journal of Heart & Lung Transplantation.

24(4):421-5, 2005 Apr.

14. Lurain NS, Fox AM, Lichy HS, Bhorade SM, Ware CF, Huang DD, Kwan SP,

Garrity ER, Chou S. Analysis from the human cytomegalovirus genomic region from

UL146 through UL147A reveals sequence hypervariability, genotypic stability, and

overlapping transcripts. Virol J. 2006 Jan 12;3(1):4

15. Bhorade SM, Jordan AM, Villanueva J, et al. A comparison of three tacrolimus

based immunosuppressive regimens in lung transplantation. American Journal of

Transplantation 2003; 3: 1570-1575.

16. Lurain N, Bhorade S. et al. Antiviral drug resistant cytomegalovirus in solid organ

transplant recipients. Journal of Infectious Disease 2002; 186: 760-768.

17. Vigneswaran WT, Sakiyalk P, Bhorade SM. Airway complications following

isolated lung transplantation. Transplantation Reviews 2002; 16 (2):87-94.

18. Bhorade SM, Lurain NS, Jordan A, et al. Emergence of ganciclovir resistant

cytomegalovirus in lung transplant recipients Journal of Heart and Lung

Transplantation 2002; 21 (12): 1274-1283.

19. Lanuza DM. Lefaiver CA. McCabe MA. Farcas GA. Bhorade SM. Garrity ER.

Functional status and medical complications during the first year post lung

transplantation (LTX). Journal of Heart & Lung Transplantation. 20(2):204, 2001

20. Bhorade SM, Sandesara C, Garrity E, Norwick L, Vigneswaran WT, Alkan S, Husain

A, McCabe MA, Yeldandi V. Quantification of cytomegalovirus viral load by the

hybrid capture assay allows for early detection of CMV disease in lung transplant

recipients. Journal of Heart & Lung Transplantation. 20(9):928-34, 2001 Sep.

21. Villanueva J, Bhorade SM, Robinson J, Husain AN, Garrity ER. Extracorporeal

Photopheresis for the Treatment of Lung Allograft Rejection Annals of Transplantation. 5(3):44-7, 2000.

22. Garrity ER, Villanueva J, Bhorade SM, et al. Reduction of acute lung allograft

rejection by daclizumab an interleukin-2 receptor antibody. Transplantation 2001; 71:

773-777.

23. Bhorade SM, Vigneswaran W , McCabe MA, Garrity ER. Liberalization of donor

criteria may expand the donor pool without adverse consequence in lung

transplantation. Journal of Heart and Lung Transplantation 19 (12): 1199-1204, 2000.

24. Christenson J, Lavoie A, O’Connor M, Bhorade S, Pohlman A, Hall JB. The

incidence and pathogenesis of cardiopulmonary deterioration following the abrupt

withdrawal of inhaled nitric oxide. American Journal of Respiratory and Critical Care

Medicine 161 (5):1443-1449,2000

25. Bhorade S, Christenson J, O’ Connor M, Lavoie A, Pohlman A, Hall JB. The

response to inhaled nitric oxide in patients with acute right heart syndromes. American

Journal of Respiratory and Critical Care Medicine 159 (2): 571-602, 1999.

26. Bhorade S, Christenson J, Pohlman A, Hall JB. The incidence of and clinical

variables associated with vancomycin resistant enterococcal colonization in

mechanically ventilated patients. Chest 115(4): 1085-1092, 1999.

Invited Review manuscripts:

1. Floreth T, Bhorade SM, Ahya VN. Conventional and Novel Approaches to

Immunosuppression. Clin Chest Med. 2011 Jun;32(2):265-77

2. Ramaprasad C, Zamora MR, Hopkins P, Bhorade SM. Influenza and other seasonal

respiratory viruses in cardiothoracic transplantation. Journal of Heart Lung

Transplantation (in press)

3. McShane PJ, Bhorade SM. Immunosuppression following lung transplantation. In:

UpToDate, Basow (ed), UpToDate, Waltham, MA, 2009

4. Floreth T, Bhorade SM. Current trends in immunosuppression. Seminars in

Respiratory and Critical Care Medicine 2010; 31:172-178.

5. Brush DR, Bhorade SM. Interstital lung disease and lung transplantation. Minerva

Pneumol 2008; 47: 53-62.

6. Stern E, Bhorade SM. Lung transplantation: the new lung-allocation system.

Expert review of respiratory medicine 2008; 2: 473-478.

7. Bhorade SM. Cyclosporine chapter in Administration and Monitoring of

Immunosuppressive Drugs in Lung Disease and Lung Transplant Patients: ACCP

Evidence-Based Clinical Practice Guidelines 2008- (in press)

8. Stern E, Bhorade SM. Immunosuppression after lung transplantation. Proceedings

of the American Thoracic Society 2009 Jan 15;6(1):47-53.

9. Meyer N, Bhorade SM. Evolving immunosuppression for lung transplantation.

Seminars in Respiratory and Critical Care Medicine 2006; 27: 470-479.

10. Orens JB, Shearon TH, Greudenberger RS, Conte JV, Bhorade SM, Ardehali A.

Thoracic organ transplantation in the United States 1995-2004. Am J Transplant

2006;6: 1188-1197

11. Bhorade SM and Lu B. Lung transplantation for interstitial lung disease. Clinics in

Chest Medicine 2004; 25; 773-782.

12. Bhorade SM, Villanueva J, Jordan A, Garrity ER. Immunosuppressive Regimens in

Lung Transplantation. Drugs of Today 2004; 40: 1003-1012.

13. Bhorade SM et al. Community respiratory viral infections in the lung transplant

recipient. The American Journal of Pulmonary Review 2003; 1:14-15.

14. Jordan AM, Bhorade SM. Lung Transplantation for Cystic Fibrosis. Current

Opinion in Organ Transplantation.2002; 7:254-259.

Abstracts:

1. H.Y. Robbins, S.M. Arcasoy, S. Bhorade, M.M. Crespo, S.M. Kawut, V.N. Lama, J.B.

Orens, S.M. Palmer, P.D. Shah, R. Shah, J.R. Sonett, L.B. Ware, A. Weinacker, K.M.

Wille, J.D. Christie, D.J. Lederer. Temporal Trends in the Prevalence of Primary Graft

Dysfunction after Lung Transplantation in the Lung Transplant Outcomes Group (LTOG)

Cohort. J Heart Lung Transplant 2011 (oral presentation)

2. J.M. Diamond, R. Feng, N. Meyer, D. Lederer, J. Lee, S. Kawut, V. Ahya, E. Cantu, S.

Palmer, A. Weinacker, S. Bhorade, V. Lama, J. Orens, J. Sonett, K. Wille, M. Crespo, D.

Weill, B. Kohl, C. Deutschman, S. Arcasoy, A. Shah, P.D. Shah, E.J. Demissie, J.

Reynolds, J. Belperio, D. Wilkes, L. Ware, J.D. Christie PTX3 Polymorphisms Are

Associated with Primary Graft Dysfunction after Lung Transplantation. J Heart Lung

Transplant 2011 (oral presentation)

3. D.J. Lederer, S.M. Kawut, N. Wickersham, C. Winterbottom, J. Diamond, S. Bhorade,

S. Palmer, J. Lee, K.M. Wille, A. Weinacker, V. Lama, M. Crespo, J. Orens, S.M.

Arcasoy, L. Ware, J.D. Christie. Higher Plasma Leptin Levels Are Associated with

Primary Graft Dysfunction after Lung Transplantation: The LTOG Obesity Study. J

Heart Lung Transplant 2011 (oral presentation)

4. J.M. Diamond, D. Lederer, S.M. Kawut, J. Lee, E. Cantu, V. Ahya, S. Palmer, A.

Weinacker, S. Bhorade, V. Lama, J.B. Orens, J. Sonett, K. Wille, M. Crespo, D. Weill,

B. Kohl, C. Deutschman, S. Arcasoy, A. Shah, P.D. Shah, E.J. Demissie, J.M. Reynolds,

J. Belperio, D. Wilkes, L. Ware, J.D. Christie. Elevated PTX3 Concentration Is

Associated with Primary Graft Dysfunction. J Heart Lung Transplant 2011 (oral

presentation)

5. M.J. Russo, K.N. Hong, A. Iribarne, J. Costa, E. Garrity, S. Bhorade, W. Vigneswaran,

J.R. Sonett Age Greater Than 70 Is Associated with Diminished Post-Lung Transplant

Survival. J Heart Lung Transplant 2011 (oral presentation)

6. T. Floreth, R. Stern, B. Laxman, E. Garrity, S. Bhorade, S.R. White. Human Leukocyte

Antigen-G Concentrations in Plasma and BALF Are Inversely Correlated to High Grade

Acute Rejection in Lung Transplantation. J Heart Lung Transplant 2011 (oral

presentation)

7. Ghassemieh, Charbeneau, Ahya, Baz, Valentine, Arcasoy, Love, Seethamraju, Alex,

Bag,. DeOliveira, Husain, Vigneswaran, Krishnan, Durazo-Arvizu, Norwick, Garrity, S.

Bhorade. Decreased CMV Infection with Sirolimus Compared to Azathioprine after

Lung Transplantation. J Heart Lung Transplant 2011 (poster presentation)

8. Zhang W, Zhou T, Machado R, Bhorade S, and Garcia JG. MicroRNAs Are Implicated

In Gene Expression Dysregulation In Lung Transplant Patients. Am. J. Respir. Crit. Care

Med., May 2011; 183: A4019. (oral presentation)

9. Stern E, Tu Y, Stern R, Marroquin B, Bhorade S, and White SR. Cyclosporine Does Not

Affect Cytokine Secretion Of Differentiated Allograft Epithelial Cells Am. J. Respir.

Crit. Care Med., May 2010;181: A6434.

10. Shah, Diamond, Ahya, Arcasoy, Belperio, Bhorade, Cantu, Crespo, Deutschman,

Demissie, Kawut, Kohl, Lama, Lederer, Lee, Orens, Palmer, Reynolds, Shah, Pali Shah,

Sonett, Wille, Weinacker, Wilkes, Ware, Weill, and Christie. Elevated Monocyte

Chemotactic Protein-1 (MCP-1) Is Associated With Primary Graft Dysfunction

Following Lung Transplantation. Am. J. Respir. Crit. Care Med., May 2011; 183: A4023.

(oral presentation)

11. Joshua M. Diamond, Rui Feng, Nuala J. Meyer, Steven M. Kawut, James C. Lee, Vivek

Ahya, Edward Cantu, Lorraine Ware, Scott M. Palmer, Sangeeta Bhorade, Vibha Lama,

Ann Weinacker, Jonathan B. Orens, Joshua Sonett, Keith M. Wille, Maria Crespo, David

Weill, Benjamin Kohl, Clifford Deutschman, Selim M. Arcasoy, Ashish Shah, Pali Shah,

E.J. Demissie, John Reynolds, John A. Belperio, David Lederer, and Jason D. Christie.

Genetic Variation In Prostaglandin E2 Family Members Is Associated With The

Development Of Primary Graft Dysfunction After Lung Transplantation. Am. J. Respir.

Crit. Care Med., May 2011; 183: A4014. (oral presentation)

12. Bhorade S, Johnson BA, Johnson ,e t al. Inhaled cyclosporine provides high lung

concentrations, low systemic exposure and is well tolerated: An interim report on the

Cyclist Clinical Trial. 9th

International congress on lung transplant Paris France

September 2010(oral presentation)

13. I.O. Gordon, S. Bhorade, W.T. Vigneswaran, P.J. McShane, E.R. Garrity, A.N. Husain :

SaLUTaRy: Survey of Lung Transplant Rejection J Heart Lung Transplant 2010 (oral

presentation)

14. Bhorade SM et al Bronchoalveolar lavage fluid Fox P3+ T cells are decreased in lung

transplant recipients with bronchiolitis obliterans syndrome. J Heart Lung Transplant

2009 (oral presentation)

15. McShane PJ, Bhorade SM et al Sirolimus is a ssociated with an increased risk of

venous thromboembolism in lung transplantation. J Heart Lung Transplant 2009(oral

presentation)

16. Bhorade SM et al Long term follow-up in the AIRSAC trial, a multicenter randomized

clinical trial in lung transplant recipients. J Heart Lung Transplant 2009(oral

presentation)

17. Bhorade SM et al Interobserver variability of acute cellular lung rejection: A review of

310 surveillance biopsies from the AIRSAC trial American Thoracic Society

2009(poster discussion)

18. Bhorade, SM, et al. Comparison of Infection Rates between Sirolimus and Azathioprine

in a Tacrolimus Based Immunosuppressive Regimen after Lung Transplantation Am J Respir Crit Care Med 2008

19. Bhorade, SM, et al. Comparison of a tacrolimus/sirolimus/prednisone regimen versus

tacrolimus/ azathioprine/prednisone immunosuppressive regimen in lung transplantation

Journal of Heart and Lung Transplantation 2008(oral presentation)

20. Bhorade SM et al. Acute rejection and infection episodes modify the chemokine milieu

in human lung allografts. American Immunology Conference 2007(oral presentation)

21. S.M. Bhorade, V. Ahya, R. Kotloff, et al. Incidence of Renal Failure in Lung Transplant

Recipients Receiving Tacrolimus and Sirolimus Immunosuppressive Regimen. Journal

of Heart and Lung Transplantation 2006

22. Lu B, Garrity ER, Ahya V, Kotloff R, Baz M, Valentine V, Arcasoy S, Love R, Bhorade

S. Utility of surveillance bronchoscopy after lung transplantation. Am J Respir Crit Care Med 2005: A892. (oral presentation)

23. Janata RJ, Bhorade SM, Villanueva J. Outcome of lung transplant recipients following

admission to a long term acute care facility. Am J Respir Crit Care Med 2005: A892. 24. Janata KR, Lu B, Sinecore J, Garrity ER, Bhorade S. Measurement of

immunosuppression by the cylex immunoassay in lung transplantation patients. Am J Respir Crit Care Med 2005: A420.

25. Lu BS, Garrity ER, Bhorade SM. Prevalence and outcome of post- transplant

lymphoproliferative disorder in lung transplantation. Am J Respir Crit Care Med 2005: A420.

26. Janata RJ, Bhorade SM, Villanueva J. Outcome of lung transplant recipients following

admission to a long term acute care facility. Am J Respir Crit Care Med 2005: A418. 27. Janata RJ, Riker D, Bhorade SM, et al. Incidence of sleep disturbances in medical

students. Am J Respir Crit Care Med 2005: A758. 28. Bhorade SM, Ahya V, et al. Six month results of sirolimus versus azathioprine in a

tacrolimus based immunosuppressive regimen in lung transplantation. J Heart Lung

Transplantation 2005: 24 S26 (oral presentation)

29. Pelletiere K, Vigneswaran WT, Bhorade S., et al. Critical pathway and strategies to

improve lung transplant outcome. Chest 2004; 126: 844s.

30. Janata KR, Lu B, Bhorade SM, et al. Reduction of Fas Ligand levels in bronchoalveolar

lavage fluid in lung transplant recipients. J of Heart Lung Transplantation 2005; 24: S54.

31. Shah SH, Vigneswaran WT, Bhorade S., et al. Reducing corticosteroid administration

decreases the incidence of opportunistic infection following lung transplantation without

increasing early rejection. Chest 2004; 126: 712s.

32. Lu BS, Yu AD, Cao GC, Garrity ER, Vigneswaran WT, Bhorade SM. Sequential gene

expression profiling of lung transplantion recipients with acute rejection. Am J Respir Crit

Care Med 2004: A505.

33. Lu BS, Yu AD, Cao GC, Garrity ER, Vigneswaran WT, Bhorade SM. Temporal gene

expression profiling of lung transplantion recipients with acute rejection. Am J Respir Crit

Care Med 2004: A271.

34. Yu AD, Bhorade SM, Lu BS, DiPietro L, Garrity ER. Evaluation of fibroblast growth

factor in lung transplant recipients with sarcoidosis. Am J Respir Crit Care Med 2004:

A102.

35. DeFay R, Villanueva J, Kramer H, Garrity E, Bhorade SM. Outcomes of lung transplant

recipients in the medical intensive care unit. Am J Respir Crit Care Med 2004: A101

36. Yu AD, BS Lu, Vigneswaran, Garrity ER, Bhorade SM. Elevated IL15 in acute lung

allograft rejection. Journal of Heart and Lung Transplantation 2004; 23: s165. (oral

presentation)

37. Lu BS, Yu AD, Cao GG, Garrity ER, Vigneswaran WT, Bhorade SM. Differential gene

expression profiling in lung transplant recipients with chronic rejection. Journal of Heart

and Lung Transplantation 2004; 23: S131. (oral presentation)

38. Bhorade SM, et al. Comparison of sirolimus versus azathioprine in a tacrolimus based

immunosuppressive regimen in lung transplantation. Journal of Heart and Lung

Transplantation 2004; 23: S113.

39. Jordan A, Bhorade SM, et al. Sirolimus for the treatment of Bronchiolitis obliterans

sydrome. Am J Respir Crit Care Med 2003;167:A611.

40. Jordan A, Bhorade SM, et al. Increased IL 15 in bronchoalveolar fluid in acute lung

allograft rejection. AST 2003

41. Yu A, Bhorade SM, et al. Evaluation of risk factors for progression of BOS-OP to BOS Am J Respir Crit Care Med 2003;167:A246.

42. Bhorade SM et al. Liberalization of donor criteria does not compromise outcomes three

years after lung transplantation. Journal of Heart and Lung Transplantation 2003;

22:143. (oral presentation)

43. Bhorade SM et al. New combination of immunosuppressive therapy decreases acute

rejection in lung transplantation. Journal of Heart and Lung Transplantation 2003;

22:426.

44. Bhorade SM.et al. A comparison of three tacrolimus based immunosuppressive regimens

in lung transplantation. Am J Respir Crit Care Med 2002;165: B3

45. Jordan A, Bhorade SM. The natural history of bronchiolitis obliterans syndrome. Am J

Respir Crit Care Med 2002;165: B3

46. Kefer J, Bhorade SM, Villanueva J et al. Effect of recombinant human erythropoietin on

hemoblobin levels of anemic lung transplant recipients. Chest 2001

47. Jordan A, Bhorade SM, Lurain NS, et al. Emergence of ganciclovir resistant

cytomegalovirus in lung transplant recipients.American Society of Transplantation

2001(oral presentation)

48. Villanueva J, Bhorade SM, et al. Acute lung allograft rejection rates with three different

immunosuppressive regimens. American Journal of Respiratory and Critical Care

Medicine 163(5): A336;2001

49. Lanuza DM, Lefaiver CA, McCabe MA, Farcas GA, Bhorade SM, Garrity ER.

Functional status and medical complications during the first year post lung

transplantation. The Journal of Heart and Lung Transplantation 20(2): A163; 2001

50. Villanueva J, Khurshid A, Bhorade SM, Garrity ER. Sleep disturbances in lung

transplant recipients. (accepted for poster presentation APSS 2001

51. N. Lurain, D. Kohn, S. Bhorade et al. CMV Antiviral Drug Resistance in Solid Organ

Transplant Recipients.

52. Villanueva J, Bhorade S, McCabe MA, Husain A, Vigneswaran W,Garrity ER. The

utility of surveillance bronchoscopy in lung transplantation. American Journal of

Respiratory and Critical Care Medicine 161 (3):A719;2000.

53. Villanueva J, Bhorade S, McCabe MA, Husain A, Vigneswaran W,Garrity ER.

Dacluzimab, an anti-interleukin receptor antibody, may decrease the acute rejection in

lung transplant patients. The Journal of Heart and Lung Transplantation 19(1): A192;

2000(oral presentation)

54. Sandesara C, Bhorade S, Garrity E, Norwick L, McCabe, Husain A, Yeldandi V. Early

detection of CMV disease by the hybrid capture assay in lung transplantation. The

Journal of Heart and Lung Transplantation 19(1): A178; 2000(oral presentation)

55. Vigneswaran V, McCabe MA, Bhorade S, Bakhos M, Hinkamp TJ, Garrity ER. Cystic

fibrosis patients may require waiting time adjustment. The Journal of Heart and Lung

Transplantation 19(1): A79; 2000

56. Bhorade S, McCabe MA, Martin KL, Lonchyna V, Arcidi J, Hinkamp T, Garrity ER.

Succesful lung transplantation with the use of marginal donors. The Journal of Heart and

Lung Transplantation 18(1): A184; 1999(oral presentation)

57. Bhorade SM, Vence C, Garrity ER, Alex C, Simpson K, Husain AN, McCabe MA,

Yeldandi V. Treatment of infections in lung transplant patients with filgrastin (G-CSF)

does not induce rejection. Transplantation 67(7): A132,1999. (oral presentation)

58. Amstadt C, Bhorade SM, McCabe MA, Vigneswaran W, Garrity ER. The efficacy of

daclizumab, an anti-interleukin receptor antibody in the prevention of acute rejection in

lung transplantation. Transplantation 67(7): A388,1999.

59. Bhorade S, Christenson J, Pohlman A, Arnow P, Hall JB. Risk factors for colonization

by vancomycin resistant enterococcus during mechanical ventilation. American Journal

of Respiratory and Critical Care Medicine 157(3): A292, 1998.

60. Bhorade S,Christenson J, Pohlman A, Arnow P, Hall JB. Incidence and associated

outcome of colonization by vancomycin resistant eneterococcus during mechanical

ventilation. American Journal of Respiratory and Critical Care Medicine 157(3): A292,

1998.

61. Christenson J, Bhorade S, Pohlman A, Spencer K, Hall JB. The use of transnasal

transesophageal echocardiography for continous monitoring of right ventricular function

in patients receiving nitric oxide. American Journal of Respiratory and Critical Care

Medicine 155(4): A440, 1997.

62. Christenson J, Bhorade S, Pohlman A, Lavoie A, Kason T, O’Connor M, Hall JB.

Treatment of acute right ventricular failure with inhaled nitric oxide. American Journal of

Respiratory and Critical Care Medicine 155(4): A703, 1997

63. Christenson J, Bhorade S, Pohlman A, Lavoie A, Wylam M, O’Connor M, Hall JB.

Discontinuation of inhaled nitric oxide in acute hypoxemic respiratory failure: Adverse

effects on gas exhange and hemodynamics. American Journal of Respiratory and Critical

Care Medicine 155(4): A745, 1997.

64. Christenson J, Bhorade S, Pohlman A, Lavoie A, Wylam M, O’Connor M, Hall JB. The

effect of lung focality on response to inhaled nitric oxide in acute hypoxemic respiratory failure. American Journal of Respiratory and Critical Care Medicine 155(4): A91, 1997.

65. Renz C, Christenson J, Bhorade S, Pohlman A, Arnow P, Hall JB Assessment of

combination prophylaxis to prevent ventilator –associated pneumonia. American Journal

of Respiratory and Critical Care Medicine 155(4): A932, 1997.

66. Renz C, Christenson J, Bhorade S, Pohlman A, Ndukwu M, Arnow P, Hall JB

Prevention of ventilator associated pneumonia: Outcome and Resource Utilization.

American Journal of Respiratory and Critical Care Medicine 155(4): A19, 1997.

Book Chapters:

1. Floreth T, Bhorade SM. Special Considerations in Lung Transplantation in older

patients. In Aging and Lung Disease in Respiratory Medicine Book Series. (in press)

2. Wickii T. Vigneswaran, Sangeeta M. Bhorade. Post Operative Care Of The Lung

Transplant Patient. Surgical Intensive Care Medicine.(Second Edition). (Eds.) John

O’Donnell and Flavio Nacul. Springer, New York, 621-628, 2009.

3. McShane PJ, Bhorade SM. Maintenance immunosuppression in lung transplantation in

Lung. In Vigneswaran WT, Garrrity ER. Lung Transplantation. Lung Biology in Health

and Disease. Informa Healthcare UK April 2010

4.. McShane PJ, Bhorade SM. Augmentation of immunosuppression in lung transplantation

in Lung Transplantation. In Vigneswaran WT, Garrrity ER. Lung Transplantation. Lung

Biology in Health and Disease. Informa Healthcare UK April 2010

5. Lu BS, Garrity ER, Bhorade SM. Cyclosporine; Tacrolimus; Sirolimus; Azathioprine;

Mycophenolate Mofetil; Corticosteroids. Lung and Heart Lung Transplantation Marcel

Dekker series

6. Dickover B, Bhorade SM, Garrity ER. Lympholytic Agents (Polyclonal

Antilymphocyte Ab, Anti-CD3 Monoclonal antibodies, Anti-CD25 Monoclonal Ab)Lung

and Heart Lung Transplantation Marcel Dekker series

7. Bhorade SM, Villanueva J, Jordan A, Garrity ER. Modern concepts of

immunosuppression in lung transplantation. In Advances in Thoracic Surgery 2002

8. Garrity ER, Vigneswaran W, Bhorade SM. Pre-Transplant Evaluation of Donor/ Organ

Procurement. In Norman DJ, Suki WN ed. Primer on Transplantation, 2nd

Ed. New Jersey:

American Society of Transplant Physicians 2001.

9. Bhorade SM, Garrity ER. Organ Sharing and Allocation: Lung and Heart/ Lung. In

Norman DJ, Suki WN ed. Primer on Transplantation, 2nd

Ed. New Jersey: American Society

of Transplant Physicians 2001.

10. Bhorade SM, Vigneswaran W, Garrity ER. Lung Transplantation at Loyola University

Medical Center. In Cecka JM, Terasaki PJ ed. Clinical Transplants 1999, UCLA Tissue

Typing Laboratory.

11. Bhorade SM. Acute Hypoxemic Respiratory Failure. In: Hall JB, Schmidt GA, Wood

LDH ed. Principles of Critical Care Companion Handbook, 2nd

Ed. New York: McGraw-

hill, Inc. Health Professional Division, 1999.

12. Bhorade SM. Critical illness in pregnancy. In: Hall JB, Schmidt GA, Wood LDH ed.

Principles of Critical Care Companion Handbook, 2nd

Ed. New York: McGraw-hill, Inc.

Health Professional Division, 1999.

13. Bhorade SM. Monitoring the respiratory system. In: Hall JB, Schmidt GA, Wood

LDH ed. Principles of Critical Care Companion Handbook, 2nd

Ed. New York: McGraw-

hill, Inc. Health Professional Division, 1999.

14. Bhorade SM. Vasoactive medications. In: Hall JB, Schmidt GA, Wood LDH ed.

Principles of Critical Care Companion Handbook, 2nd

Ed. New York: McGraw-hill, Inc.

Health Professional Division, 1999.

Case Reports/Invited articles:

1. Bhorade SM. Lung Transplantation. (Book Review) Respiratory Care 2004; vol 49 ,

#10.

2. Bhorade S. and Schmidt G. Dealing with the risk of venothromboembolism (VTE) in

women using oral contraceptives. Journal of Respiratory Disease 19 (1): 8-11, 1998.

3. Hinkes E, Bhorade S, Wood LDH, Ndukwu IM. Young Adult with near-fatal

pneumonia caused by Adenovirus Serotype 7. Respiratory Care 44:524-527, 1999.

Other:

1. Walia R, Bhorade SM Practical Reviews.

2. Bhorade S, McShane P. Bronchiectasis. BMJ Point-of-Care 2009;

www.pointofcare.bmj.com. (Last accessed May, 2009)

3. Contributor to the ATS Best of the Web: Educational resources for lung transplantation

for health care professionals (10/2007- present)

4. Contributor to the ATS Basic Science Journal Club (12/00) Contributor to the ATS CME

web site (7/99,)

INVITED PRESENTATIONS AT NATIONAL/ INTERNATIONATIONAL

MEETINGS:

1. American Society of Transplantation. Co-moderator-Bronchiolitis Obliterans April

2002

2. American Thoracic Society. Lung Transplantation. Modern concepts of

immunosuppression Atlanta Georgia May 2002

3. American College of Chest Physicians. The management and diagnosis of acute and

chronic rejection. San Diego Nov 2002

4. International Congress on Lung Transplantation. Multicenter Rapamune trial in lung

transplantation. Paris France Sept 2002

5. International Congress on Lung Transplantation. Liberalization of donor criteria:

What limits to preserve good results? Paris France Sept 2002

6. American Thoracic Society. Bronchiolitis obliterans: diagnosis and therapeutic

options. Seattle WA May 2003

7. American College of Chest Physicians. What is the optimal immunosuppressive

regimen in lung transplantation? Orlando Fla Nov 2003

8. American Thoracic Society. New Immunosuppressives: Can they prolong survival

and improve quality of life? May 2004

9. American Thoracic Society. Infectious Complications after lung transplantation May

2004

10. International Congress on Lung Transplantation. Sirolimus in lung transplantation.

Paris France Sept 2004

11. International Congress on Lung Transplantation. Malignancy after lung

transplantation Paris France Sept 2004

12. American College of Chest Physicians Refractory rejection in the critically ill lung

transplant recipient. Seattle, WA Oct 2004

13. American Thoracic Society. San Diego, CA May 2006 Moderator Lung

Transplantation

14. World Transplant Conference Boston, MA July, 2006 Moderator Lung

Transplantation

15. International Society of Heart and Lung Transplantation. Utility of Cylex Immunoassay

in lung transplantation. San Francisco April 2007

16. American Thoracic Society. Effective control of Acute Rejection. San Francisco May

2007

17. American College of Chest Physicians. Lung transplantation for the hospitalized

patient: Is it ever appropriate? Con Chicago October 2007

18. American College of Chest Physicians. Diagnosis and treatment of fungal infections

in lung transplant recipients. Philadelphia PA October 2008

19. Catalan Transplant Society. Lung Allocation Score-It’s effect on pre- and post-

transplant mortality. Barcelona Spain February 2009

20. Catalan Transplant Society. Expanded donor criteria: Where is the limit? Barcelona

Spain February 2009

21. International Society of Heart and Lung Transplantation. New approaches to

monitoring the extent of immunosuppression Paris France April 2009

22. American Thoracic Society. Postgraduate course: Acute rejection: prevention,

detection and management Lung transplantation: State of the Art. San Diego CA May

2009

23. International Society of Heart and Lung Transplantation. Lymphocytic bronchiolitis.

Moderator Chicago IL April 2010

24. International Congress on Lung Transplantation. Recent results of the azathioprine

and rapamune trial Paris France Sept 2010

25. International Congress on Lung Transplantation. Quality of life after lung

transplantation Paris France Sept 2010

26. American College of Chest Physicians. What transplant drugs can only be given by

transplant centers? Vancouver Canada November 2010

27. American College of Chest Physicians. Acute immunosuppressive therapy-related

complications and considerations in the critically ill transplant recipient Vancouver

Canada November 2010

28. International Society of Heart and Lung Transplantation. Ganciclovir resistant CMV

disease. San Diego CA April 2011

29. International Society of Heart and Lung Transplantation. Bortezomib in Antibody

mediated rejection. San Diego CA April 2011

30. American Thoracic Society. Postgraduate course: Post transplant

immunosuppression. Denver CO May 2011

31. American Thoracic Society. Meet the Professor: Evolving concepts in the

pathogenesis and treatment of Bronchiolitis obliterans syndrome. Denver CO May 2011

INVITED GRAND ROUNDS:

1. Internal Medicine Grand Rounds, Loyola University of Chicago Medical Center. Lung

Transplantation-Who, When and Why? August, 1999.

2. Internal Medicine Grand Rounds, Loyola University of Chicago Medical Center.

Emerging concepts in interstitial pneumonitis July 2003

3. Internal Medicine Grand Rounds, Christ Hospital. Pulmonary infiltrates in a 15 year

old woman. Chicago, IL January 2005

4. Internal Medicine Grand Rounds, Our Lady of the Resurrection Hospital. Community

Acquired Pneumonia Chicago, IL February 2005

5. Internal Medicine Grand Rounds, Chicago Medical School. Surgical Treatments for

COPD. North Chicago, IL August 2006

6. Internal Medicine Grand Rounds, St Joseph Hospital. Lung Transplantation 2008: An

Update Chicago February 2008

7. Internal Medicine Grand Rounds, University of Texas, Galveston. Lung

Transplantation: The good, the bad and the better…. July 2008

8. Pulmonary Grand Rounds. University of Miami, Miami Florida. Lung

Transplantation: A new era. February 2009

9. Pulmonary Grand Rounds. Rush University. Lung Transplantation: An update.

December 2009

10. Internal Medicine Grand Rounds, Chicago Medical School. Lung Transplantation for

COPD. North Chicago, IL September 2010

11. Transplant Medicine Grand Rounds. Methodist Hospital. Baylor College of

Medicine. The Changing Face of lung transplantation. November 2010

12. Pulmonary Grand Rounds, Loyola University of Chicago Medical Center. The

Changin Face of lung transplantation. March 2011

INVITED LECTURES (LOCAL)

1. National Sarcoidosis Association Annual Awareness Conference. Sarcoidosis and

Lung Transplantation. June, 1999.

2. Cystic Fibrosis Awareness Day. Cystic Fibrosis and Lung Transplantation.

September, 1999.

3. Chicago Medical Society Midwest Clinical Conference 2000: Selection criteria for lung

transplant recipients. February 2000.

4. State of the Art immunosuppression in Transplantation; Peoria IL The use of sirolimus

in solid organ transplantation. February 2001

5. Annual Far Eastern Internal Medicine Meeting; Chicago, IL: Asthma September 2001

6. End stage lung disease symposium; Loyola University Medical Center (course

director): Idiopathic pulmonary fibrosis. November 2001

7. Alpha 1 Antitrypsin Society. Alpha 1 antitrypsin and lung transplantation Chicago

June 2002

8. End stage lung disease symposium. Loyola University Medical Center (co-course

director): Pulmonary hypertension September 2002

9. Alpha 1 Antitrypsin Society. Alpha 1 antitrypsin and lung transplantation Chicago

June 2003

10. Cleveland Clinic Pulmonary Conference. Update in lung transplantation. Cleveland,

OH February 2006

11. University of Illinois Pulmonary Conference. Lung Transplantation. Chicago, IL

October 2006

12. Chicago Medical School. Advances in COPD Symposium. Improving outcome in

COPD Chicago, IL November 2006

13. Advanced Lung Disease Symposium. Course Moderator. Medical Complications

after lung transplantation. (50 local pulmonologists ¾ day conference) Chicago October

2008

14. University of Chicago Undergraduate Course. Lung Transplantation January 2011

GRANTS:

7/06-7/11 5R01HL081619 NIH/ NHLBI

PI- J Christie MD

Co-investigator- S. Bhorade, MD

Genetics of primary graft dysfunction

7/09-7/11 1R21AI083527-01 NIH/NIAID

PI- Steven White, MD,

Co-investigator- S. Bhorade, MD

Role of epithelial HLA-G in lung transplantation

2/02-12/09 Fujisawa Award- $1,500,000

Multicenter lung transplant study: Comparison of a de novo tacrolimus/sirolimus/prednisone

regimen versus a tacrolimus/azathioprine/prednisone immunosuppressive regimen in lung

transplantation.- P.I.- S. M. Bhorade,MD

11/06-11/07 U Chicago DOM Lung Transplant Research Award Correlation of Lung

Biopsy, BAL, and High Resolution CT Scan in Lung Transplantation. Can we Help

Diagnose Acute Rejection and Better Predict Bronchiolitis Obliterans? Garrity ER (PI),

Bhorade (Co-investigator)

11/06-11/07 U Chicago DOM Lung Transplant Research Award Bhorade (PI)

Comparison of TLR signaling and Treg infiltrating profiles between stable and infected lung

allografts in human lung transplant recipients

2/02-12/06 RO1 HLO72871-01 NIH Award Matalon (PI)

Modulation of innate immunity in lung transplantation by tacrolimus and sirolimus.

Role: Consultant

4/01-4/04 ALA grant- $35,000 x 3years

Pathogenesis of cytomegalovirus in lung transplantation- P.I- Nell Lurain, PhD, Co-

investigator- S.M. Bhorade, MD

7/00-6/05 RO1 NR05284-03 NIH Award - $1,700,000

Predictors of Quality of Life: Lung Transplant Patients-P.I.- Dorothy Lanuza,RN,PhD, Co-

investigator- S. M. Bhorade, MD

1/00-6/01 Fujisawa Award- unrestricted grant- $75,000

Evaluation of induction therapy with a humanized monoclonal antibody in addition to triple

drug immunosuppressive therapy in lung transplantation-a single center pilot study- P.I.- S.

M. Bhorade,MD, Co-investigator- Edward Garrity, Jr., MD .

1/00-6/00 RFC grant (Bane)- $20,000

Factors predicting quality of life in lung transplant patients: A longitudinal study- P.I. SM

Bhorade, MD, co investigator- Dorothy Lanuza

4/01-4/03 Wyeth-Ayerst Award- unrestricted grant-$60,000.

Conversion to sirolimus in the treatment of Bronchiolitis Obliterans Syndrome in lung

transplantation- P.I.- S. M. Bhorade,MD

CONTRACTS:

A Study to Evaluate Viral Quantity and Shedding as a Function of Time in Adult Lung

Transplant Patients with RSV Infection.P.I. SM Bhorade, MD

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the

Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Carein Lung

Transplant Patients Infected with Respiratory Syncytial Virus (RSV) P.I. SM Bhorade, MD

A Multi-center, Randomized, Controlled Study to Demonstrate the Efficacy and Safety of

Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-

Free Survival Following Lung Transplantation P.I. SM Bhorade, MD

A Phase III, Randomized, Double-blind Comparison of Oral Valganciclovir and Placebo for

Prevention of CMV Infection After Lung Transplantation P.I.- Edward Garrity, Jr., MD, CO

P.I.- SM Bhorade, MD

A Long-Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having

Completed AMB-320 or AMB-321. P.I. SM Bhorade, MD-closed

A Phase II, randomized, Double-Blind, Placebo-Controlled, Study of the Safety and Clinical

Effects of (Gleevec Imatinib Mesylate) Administered Orally in Patients with Idiopathic

Pulmonary Fibrosis. P.I.- SM Bhorade, MD-closed

Randomized, double-blind, placebo-controlled, phase III study of the safety and efficacy of

subcutaneous recombinant interferon gamma-1b in patients with idiopathic pulmonary

fibrosis. P.I.- S. M. Bhorade, MD-closed

Three year randomized multi-center double blind parallel group study of the efficacy and

safety of SDZ RAD, azathioprine as adjunctive immunosuppressive therapy to inhibit the

decline of pulmonary function in lung or heart/lung transplant recipients at risk for

developing bronchiolitis obliterans syndrome- P.I.- Edward Garrity, Jr., MD, Co-

investigator- S.M. Bhorade, MD direct cost-$37,000.-closed

One year randomized multi-center open labelled parallel group study of the efficacy and

safety of RAD001 tablets versus antithymocyte globulin and azathioprine in lung or

heart/lung transplant with bronchiolitis obliterans syndrome- P.I-Edward Garrity,Jr., MD,

Co-investigator- S.M. Bhorade, MD direct cost-$7,000-closed.